In the biomedical sciences, antibodies are essential tools used in a wide range of applications, such as the identification of biomolecules in biological fluids, tissues, and cells, protein purification, the functional removal of proteins from cells and cell extracts, and therapeutic and diagnostic medicine. Recombinant antibodies, often known as recmAbs, are monoclonal antibodies produced in vitro with the use of artificial genes. Unlike monoclonal antibodies (mAbs), which are made utilizing conventional hybridoma-based methods, the manufacture of recmAb does not need the use of hybridomas or animals. Both monoclonal and recombinant antibodies are useful therapeutic agents for cancer, autoimmune disorders, and a wide range of other illnesses. They may be employed in biomedical science and toxicological research.
As presented at the seminar on Antibody Validation: Standards, Policies, and Practices at Asilomar, CA September 25-27, 2016, we are in the process of converting all our monoclonal antibodies produced by hybridoma technology to recombinant antibodies (recmAbTM) to obtain consistent results and to prevent lot-to-lot variations. Recombinant antibodies, including Recombinant Biosimilar Antibodies, Recombinant Rabbit Antibodies, and Recombinant Mouse Antibodies, have been developed by Abeomics and help scientists and researchers conduct studies more successfully.